Skip to main content
OpenTrials
Completed

NCT Number: NCT07452757

To Evaluate Efficacy and Safety of Proprietary Healthy Diet Combinations for Weight Management in Overweight Volunteers

This is an open-label, four-arm, randomized, controlled clinical study designed to evaluate the efficacy and safety of a structured Weight Management Program (WMP) in overweight and obese adults with a body mass index (BMI) ≥ 23 kg/m² (Asian Indian ethnicity cut-off). A total of 140 subjects will be enrolled and randomized equally into four arms: one control arm and three intervention arms with varying levels of nutritional intervention.

The Weight Management Program comprises three sequential phases: a pre-engagement gut-reset phase (10 days), an intensive intervention phase (30 days), and a maintenance phase (60 days). The intervention arms will receive combinations of meal replacements, protein supplements, fiber supplements, probiotics, and multivitamin-multimineral supplements, along with nutritional and behavioral counseling, calorie-deficit diet plans, and prescribed physical activity. The control arm will follow a free-living lifestyle without intervention.

The primary efficacy outcome is the proportion of subjects demonstrating a reduction in body weight and/or BMI from baseline to the end of the intensive phase. Secondary outcomes include changes in body weight and BMI at the end of the maintenance phase, maintenance of weight loss, changes in body composition, waist circumference, waist-hip ratio, lipid profile, metabolic parameters, physical activity, quality of life, and safety outcomes including adverse events.

The study aims to generate evidence on the effectiveness and safety of a holistic, lifestyle-based weight management program incorporating nutritional supplementation, dietary modification, physical activity, and behavioral support in overweight and obese individuals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Overweight (BMI > 25) Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

20 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sapthagiri Institute of Medical Sciences & Research Centre

Bangalore, Karnataka, 560090, India

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Male and female subjects age between 20 to 45 years
  • Non-pregnant and non-lactating
  • Body Mass Index (kg/m2)- ≥ 23 (considered overweight/obese as per the ethnicity cut off values for Asian Indians)
  • Following stable eating habits
  • Not on any medication that can affect Lipid profile, body composition or weight
  • Nonalcoholic and non- smoker
  • Subjects who are willing to sign the informed consent and comply with study requirement of meal replacements strictly
  • Women in the reproductive age group- should be agreeing to follow standard contraceptive measures
  • Individuals who are seriously motivated to lose weight and willing to be part of any one of the interventions where Protein drink with buttermilk, skimmed milk or water OR 1 Meal replacement OR 2 Meal replacement would be given.

Exclusion criteria

  • - On medication/ HRT (Hormone Replacement Therapy)
  • Suffering from endocrine hypothalamic- pituitary disease, women with PCOS, adrenal disorder, hypothyroidism,
  • Subjects with Diabetes type 1 or 2 to be excluded
  • Women in the reproductive age group not willing to use standard contraceptive measures.
  • Other conditions like CKD, stones, liver dysfunction (with elevated enzyme levels), history of cancer, eating disorders, chronic gastrointestinal disorders (IBD or celiac), metabolic disorders like hypertension, CVDs- that might impair the outcomes
  • Malignancy which is currently active or in remission for less than five years after last treatment
  • Unstable weight (± 5 % fluctuation in their body weight for past 8-weeks at study entry)
  • Have undergone gastroplasty or weight reducing surgery
  • Subjects who have participated in another clinical study within the past 30 days prior to screening or are likely to simultaneously participate in another clinical study.
  • Practicing any structured commercial weight management program/ intermittent fasting or any diet regime in the last 30 days prior to screening.
  • Patients who are doubtful to comply with study procedures for mental, psychological or social reasons.

Treatment and study plan

Arm II

Dietary Supplement

I. Investigational Product Morning- PRP-02 (1 scoop) + AND-16 Afternoon- PRP-02 (1 scoop) Night-PRP-02 (1 scoop) + FBR-18 (1 scoop) +PRO-19 II. Nutritional+ Behavioral counselling (Audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60-minute exercise 5 days a week or 150-300-minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)

Arm III

Dietary Supplement

I. Investigational Product - Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon - as per diet plan Night- FBR- 18 (1 scoop) +PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150 - 300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)

Arm IV

Dietary Supplement

I. Investigational Product Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon-BDK-01+ Skimmed milk powder (Only during intensive phase, in maintenance phase switch to 1 meal replacement only) Night-FBR- 18+PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150-300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)

Primary outcomes

  1. Change in Body Weight

    Time frame: Baseline (Day 1) to end of intensive phase (Day 30)

    To assess the number and percentage of subjects demonstrating a reduction in body weight from baseline to the end of the intensive phase across intervention and control arms.

Secondary outcomes

  1. Change in BMI During Maintenance Phase

    Time frame: Baseline (Day 1) to end of study (Day 90)

    To assess the number and percentage of subjects demonstrating a reduction in BMI from baseline to the end of the maintenance phase, and the proportion of subjects maintaining weight loss achieved during the intensive phase.

  2. Change in Body Fat Percentage

    Time frame: Baseline (Day 1) to end of study (Day 90)

    To evaluate the change in body fat percentage from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.

  3. Change in Waist Circumference

    Time frame: Baseline (Day 1) to end of study (Day 90)

    To assess the change in waist circumference from baseline to the end of the study and to compare the mean change between intervention and control arms.

  4. Change in Total Cholesterol

    Time frame: Baseline (Day 1) to end of study (Day 90)

    To evaluate the change in total cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.

  5. Change in Quality of Life

    Time frame: Baseline (Day 1) to end of study (Day 90)

    Change from baseline in quality of life assessed using the World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) questionnaire from baseline to the end of the study. The WHOQOL-BREF is a validated 26-item questionnaire that assesses four domains: physical health, psychological health, social relationships, and environment. Domain scores are transformed to a 0-100 scale, where higher scores indicate better quality of life.

  6. Incidence of Adverse Events

    Time frame: From baseline (Day 1) to end of study (Day 90)

    To assess the incidence, severity, and relationship of adverse events reported during the study period across all study arms.

  7. Change in Muscle Mass

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in muscle mass from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.

  8. Change in Fat-Free Mass

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in fat-free mass from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.

  9. Change in Visceral Fat Level

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in visceral fat level from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.

  10. Change in Waist-to-Hip Ratio

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To assess the change in waist-to-hip ratio from baseline to the end of the study and to compare the mean change between intervention and control arms.

  11. Change in Skinfold Thickness

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To assess the change in skinfold thickness from baseline to the end of the study and to compare the mean change between intervention and control arms.

  12. Change in Triglycerides

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in triglyceride levels from baseline to the end of the study and to compare the mean change between intervention and control arms.

  13. Change in High-Density Lipoprotein (HDL) Cholesterol

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in HDL cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.

  14. Change in Low-Density Lipoprotein (LDL) Cholesterol

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in LDL cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.

  15. Change in Fasting Blood Glucose

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in fasting blood glucose levels from baseline to the end of the study and to compare the mean change between intervention and control arms.

  16. Change in Glycated Hemoglobin (HbA1c)

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in HbA1c levels from baseline to the end of the study and to compare the mean change between intervention and control arms.

  17. Change in Serum Insulin

    Time frame: Baseline (Day 1) to End of Study (Day 90)

    To evaluate the change in fasting serum insulin levels from baseline to the end of the study and to compare the mean change between intervention and control arms.

Sponsors and collaborators

Lead sponsor

Bioagile Therapeutics Pvt. Ltd.

Industry

Registry information

Official study title

To Evaluate the Efficacy and Safety of Weight Management Program in Overweight/Obese Individuals: A 4 Arm Open Label Randomized Controlled Clinical Study

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Mar 5, 2026
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.